Silvia Bozzarelli

Dr. Silvia Bozzarelli


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2012 in Journal of Hepatology
Verified
Journal Article
Closed access
NPNicola Personeni
Nicola Personeni
SBSilvia Bozzarelli
Silvia Bozzarelli
TPTiziana Pressiani
Tiziana Pressiani
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
MTMaria Chiara Tronconi
Maria Chiara Tronconi
ASArmando Santoro
Armando Santoro

17 November 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
FPFilippo Pietrantonio
Filippo Pietrantonio
RMR. Miceli
R. Miceli
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
SLSara Lonardi
Sara Lonardi
GAG. Aprile
G. Aprile
Chiara CremoliniChiara Cremolini
Chiara Cremolini
Regorafenib and TAS-102 have recently demonstrated statistically significant survival gains in patients with refractory metastatic colorectal cancer (mCRC). Life expectancy ≥12 weeks was an inclusion criterion in registrative trials, and the identification of proper clinical selection tools for the daily use of these drugs in heavily pre-treated patients is needed to improve the cost-benefit ratio. We aimed at building a nomogram able to predict death probability within 12 weeks from the date of assessment of refractory mCRC. Four hundred eleven refractory mCRC patients with ECOG performance status (PS) ≤2 receiving regorafenib, TAS-102 or other treatments were used as developing set. Putative prognostic variables were selected using a random forest model and included in a binary logistic model from which the nomogram was developed. The nomogram was externally validated and its performance was evaluated by examining calibration (how close predictions were to the actual outcome) and discriminative ability (Harrell C index) both on developing (internal validation) and validating (external validation) sets. Four variables were selected and included in the nomogram: PS (P < 0.0001), primary tumor resection (P = 0.027), LDH value (P = 0.0001) and peritoneal involvement (P = 0.081). In the developing set, the nomogram discriminative ability was high (C = 0.778), and was confirmed in the validating set (C = 0.778), where the overall outcome was better as a consequence of the enrichment in patients receiving regorafenib or TAS-102 (46% versus 34%; P < 0.0001). Our nomogram may be a useful tool to predict the probability of death within 12 weeks in patients with refractory mCRC. Based on four easy-to-collect variables, the ‘Colon Life’ nomogram and free app for smartphones may improve mCRC patients’ selection for later-line therapies and assist researchers for the enrollment in clinical trials in this setting.


30 March 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
RBRita Balsano
Rita Balsano
VZValentina Zanuso
Valentina Zanuso
APAngelo Pirozzi
Angelo Pirozzi
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
SBSilvia Bozzarelli
Silvia Bozzarelli
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease with a poor 5-year overall survival rate (~10%). The revolution of immunotherapy in clinical oncology has not substantially changed clinical outcome for patients with PDAC. Despite outstanding efforts, neither immune checkpoint inhibitors (ICIs) alone, nor in combination with chemotherapy or targeted therapies have shown encouraging results. This failure mirrors the lack of knowledge about the real key players of immune system senescence and the complexity of the tumor microenvironment in PDAC. However, some hope can be derived from PARP-inhibitor combinations, vaccines, and CAR-T-cells therapy. In this review, we comprehensively summarize the latest updates about the use of ICIs in PDAC, focusing on clinical evidence and ongoing studies highlighting explanations for the failure of immunotherapy and possible solutions.

1 April 2013 in The Oncologist
Verified
Journal Article
Open access
PDF file
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
TPTiziana Pressiani
Tiziana Pressiani
CBCorrado Boni
Corrado Boni
CCCarlo Carnaghi
Carlo Carnaghi
ECElena Rota Caremoli
Elena Rota Caremoli
Armando SantoroArmando Santoro
Armando Santoro
Background. Sorafenib has proven survival benefits in patients with advanced hepatocellular carcinoma (HCC). The viability of continuing sorafenib at a higher dosage in patients who experienced radiologic disease progression was investigated. Methods. Patients who experienced disease progression while on sorafenib 400 mg twice daily were randomized to sorafenib 600 mg twice daily (n = 49) or best supportive care (n = 52). The primary end point was progression-free survival (PFS). Time to progression, overall survival, and safety were also evaluated. Results. The study did not meet its primary end point. The difference in PFS between the sorafenib arm (3.91 months) and the best supportive care arm (2.69 months) did not reach statistical significance (p = 0.086). Adverse events were mainly grade 1–2 and similar across both groups. In the sorafenib arm, the most frequent events were diarrhea (80%), weight loss (75%), fatigue (67%), hand-foot-skin reaction (49%), abdominal pain (37%), and stomatitis (26%). Conclusions. Escalated-dose sorafenib in patients with advanced HCC who progressed while on sorafenib, failed to provide any clinical benefit. Second-line treatment still remains an open issue to be explored in appropriate clinical trials.

9 April 2013 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
NPNicola Personeni
Nicola Personeni
Lorenza RimassaLorenza Rimassa
Lorenza Rimassa
TPTiziana Pressiani
Tiziana Pressiani
ADAnnarita Destro
Annarita Destro
CLClaudia Ligorio
Claudia Ligorio
Armando SantoroArmando Santoro
Armando Santoro